Nikarin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nikarin

What is Nikarin? (Miconazole Nitrate)

Property Description
Active ingredient Miconazole Nitrate (INN)
Form Topical cream, gel, powder, or suppository
Pharmacological class Imidazole Antifungal
General Purpose Antimycotic therapy (treating fungal growth)
Origin Synthetic

What Type of Medicine Is Nikarin (Miconazole Nitrate)?

Nikarin is a specific synthetic pharmaceutical preparation based on the active ingredient Miconazole Nitrate, which is recognized globally as an Imidazole Antifungal. This classification, which is clinically recognized for its efficacy against a wide range of common fungal pathogens, defines the medicine's core purpose. Nikarin is positioned as an agent for general antimycotic therapy, often serving as a primary topical solution for local fungal proliferation. The compound itself is a single-ingredient product, focusing exclusively on the antifungal action of Miconazole Nitrate.

Composition and Physical Form

Nikarin is formulated as a localized, topical agent, with delivery systems customized for the application site. Its common forms include a cream, gel, and specific preparations like a vaginal suppository or oral gel. These preparations use various hydrophilic and lipophilic vehicles to ensure the stable delivery of the active component. For instance, the oral gel form is typically reserved for addressing candidiasis of the oral mucosa, a specific use scenario where the drug's localized effect is highly beneficial. These topical and mucosal preparations are designed to deliver the Miconazole Nitrate directly to the affected tissue, thereby avoiding unnecessary systemic exposure.

General Therapeutic Purpose

The general therapeutic purpose of Nikarin is the control and resolution of fungal growth by exerting both a fungistatic (growth-inhibiting) and fungicidal (fungal cell-killing) action. Miconazole Nitrate achieves this by interfering with the synthesis of ergosterol, an essential component of the fungal cell membrane. This targeted mechanism ultimately leads to the efficient suppression of the fungal organism's ability to grow, spread, and maintain its structure, thereby serving the general benefit of clearing the underlying mycotic condition.

What side effects are possible with Nikarin?

Possible Side Effects and Safety Information

The safety profile for Nikarin (Miconazole Nitrate) is primarily characterized by effects observed at the site of application. Adverse reactions are classified according to frequency based on official government regulatory documents.

Local effects, such as oral discomfort, burning sensation, or pain at the application site, are classified as very common for certain formulations (ge 10%). Systemic effects are less frequent but documented. Reactions classified as common (1% to 10%) include headache, diarrhea, nausea, and vomiting, categorized under Gastrointestinal and Nervous System disorders.


Documented Serious Adverse Reactions

Official labeling records rare, but clinically significant, risks. These include severe hypersensitivity reactions and anaphylaxis. Additionally, the serious cutaneous adverse reactions (SCARs) of Toxic Epidermal Necrolysis, Stevens-Johnson syndrome, and Acute Generalized Exanthematous Pustulosis have been documented in post-marketing surveillance reports.

Critical Safety Constraint

A high-level safety constraint involves co-administration with oral anticoagulants (e.g., warfarin). The product may enhance the anticoagulant effect, leading to an increased risk of bleeding events and requiring close monitoring of prothrombin time and International Normalized Ratio (INR) as mandated by regulatory authorities.

Population-Specific Safety Cautions

The official safety information includes cautions for specific populations. Use during pregnancy is advised only after determining that the potential benefit outweighs the risk. Lactating women should also exercise caution. For pediatric use, safety and efficacy are not established in certain age groups, and use in infants under four weeks is generally not recommended.

Overdose and Emergency Response

The regulatory information for Nikarin (Miconazole Nitrate) overdose focuses primarily on the outcomes of accidental ingestion or excessive use, given its application as a topical and mucosal agent.

Overdose Entity Map (High-Level) Regulator-Documented Statement
Documented Overdose Presentations Excessive topical use may result in local manifestations of skin irritation, including redness and a burning sensation. Accidental ingestion of the product has been documented to cause vomiting and diarrhoea.
Population-Specific Overdose Notes In infants and young children using the oral gel formulation, there is a distinct risk of choking or suffocation from improper application. For patients concurrently taking oral anticoagulants (e.g., warfarin), increased systemic exposure may lead to an enhanced anticoagulant effect, posing a bleeding risk.
Emergency-Response Statements Urgent medical attention is required if accidental oral ingestion occurs. If the person is unresponsive, has collapsed, or is not breathing, emergency services must be contacted immediately. Poison Control Center contact is also mandated when the product is swallowed.
Supportive Management Regulatory documents state that treatment for overdose is symptomatic and supportive. A specific antidote is not available for miconazole overdose, thus limiting management to general supportive care.

Connection to the overall overdose profile: The official overdose profile is structured around defined local and gastrointestinal presentations, along with specific, severe complications tied to systemic absorption or physical hazard. The guidance emphasizes that due to the lack of a specific antidote, regulatory-mandated management relies entirely on seeking immediate medical help and providing supportive measures based on the patient's presentation.

Therapeutic Uses of Nikarin

What Nikarin Treats: Main Uses and Benefits

Nikarin is a prescribed medication intended for use in adult patients who have moderately to severely active rheumatoid arthritis (RA). It is utilized in individuals who have not responded adequately to or cannot tolerate other types of disease-modifying antirheumatic drugs (DMARDs).


Therapeutic Goals

  • Addresses Signs and Symptoms: Nikarin is associated with supporting the reduction of key manifestations of active RA, which may include joint pain and swelling.
  • Supports Structural Integrity: The treatment is indicated to support the slowing of structural damage progression in the joints of adult patients with this condition.

Nikarin also serves as a therapeutic option for patients diagnosed with Cryopyrin-Associated Periodic Syndromes (CAPS), which are rare, genetically-driven inflammatory disorders. Specifically, it is utilized for managing Neonatal-Onset Multisystem Inflammatory Disease (NOMID), a form of CAPS, and Deficiency of Interleukin-1 Receptor Antagonist (DIRA). The goal of using Nikarin in these conditions is to help manage active inflammation.


Quick Facts

  • Adult Rheumatoid Arthritis (RA): Indicated to support the reduction of signs and symptoms and to support slowing the progression of joint structural damage.
  • Cryopyrin-Associated Periodic Syndromes (CAPS): Utilized in the management of two forms: Neonatal-Onset Multisystem Inflammatory Disease (NOMID) and Deficiency of Interleukin-1 Receptor Antagonist (DIRA).
  • Overall Goal: The treatment's primary function is to support the management of certain inflammatory responses associated with the approved conditions.

Eligibility and Restrictions for Use

Official Eligibility Profile (Based on Regulatory Documents)

This section outlines the population eligibility and non-eligibility information for NIKTIMVO (axatilimab-csfr), as defined by authoritative governmental regulatory sources, such as the U.S. FDA Prescribing Information. The medicine has no explicitly listed absolute contraindications.


Eligibility Status Summary

Population Group Regulatory Status Constraint Basis
Adults and Children Eligible Must weigh at least 40 kg (88.2 lbs)
Pediatric Patients Use Not Established Children weighing less than 40 kg
Pregnant Women Conditional/Risk May cause fetal harm (requires verification and counseling)
Lactating Mothers Not Recommended Advised not to breastfeed for 30 days post-dose

Specific Eligibility Restrictions

  1. Reproductive Potential: Females must have a negative pregnancy test before starting treatment. They must also use effective contraception throughout therapy and for 30 days after the final dose, due to the regulatory classification that the drug may cause harm to a fetus.
  2. Infusion Reactions: Patients with a history of an infusion-related reaction to this medicine require premedication (an antihistamine and an antipyretic) before each subsequent infusion.

The regulatory profile clearly establishes specific weight-based minimums for use and mandatory reproductive health constraints for female patients, defining the boundaries for who can safely be treated.

What should I know about interactions with other medicines?

Nikarin Interactions with other medicines and products

Official regulatory documents detail specific drug and substance categories that interact with Nikarin, which may require careful management or result in a restriction on concurrent use.

Documented Interacting Categories

Interaction Classification Interacting Products/Classes Constraints and Requirements
Do Not Combine Phosphodiesterase 5 (PDE5) inhibitors (e.g., sildenafil, tadalafil, vardenafil); Soluble Guanylate Cyclase Stimulators (e.g., riociguat) Concurrent use is officially documented as restricted due to the potential for a severe drop in blood pressure.
Use With Caution Antihypertensive agents; other medicinal products with blood pressure-lowering effects (e.g., alcohol, vasodilators, tricyclic antidepressants); Corticosteroids; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Caution is advised as the blood pressure-lowering effect may be increased. Concurrent use with NSAIDs or corticosteroids has been associated with reports of severe gastrointestinal complications, including perforation.

Population-Specific Notes

  • Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency: The drug should be used with caution in patients with G6PD deficiency. Its metabolism can lead to the formation of nitrites, which may trigger a condition called methemoglobinemia in this specific patient group.

Overview of Regulatory Profile

The official interaction profile is characterized by mandatory restrictions on co-administration with other potent vasodilators, reflecting a highly significant blood pressure risk. Additionally, the documentation mandates caution when the drug is used with common medications like NSAIDs and corticosteroids due to the risk of severe gastrointestinal complications, ensuring practitioners are aware of procedural constraints for safe use.

Mechanism of Action

Nikarin functions by targeting the mevalonate pathway, a critical metabolic route within human cells. Its primary biological target is the enzyme farnesyl pyrophosphate synthase (FPPS). Nikarin acts as a competitive analogue, engaging in a specific interaction type by binding to the active site of FPPS. This binding directly inhibits the enzyme's catalytic function.

The resulting inhibition of FPPS causes a significant reduction in the synthesis of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), key intermediates in the mevalonate pathway modulation. The decrease in FPP and GGPP prevents the post-translational modification, known as prenylation, of small signaling proteins such as Ras and Rho GTPases. This lack of prenylation in the mechanistic cascade renders these proteins inactive and unable to anchor to the cell membrane. The consequence is the disruption of intracellular signaling pathways that govern cell survival and function, leading to a system-level physiological consequence of modulating bone remodeling dynamics.

Dosage and Administration Information

How to Use Nikarin (Nicorandil): Official Administration Guidelines

This section outlines the official, regulatory instructions for administering Nikarin (Nicorandil) tablets as established by governmental agencies, focusing strictly on the procedural aspects of use.


Administration Details

Classification Detail
Route of Administration Oral (tablet)
Frequency Pattern Usually twice daily (morning and evening)
Timing in relation to meals May be taken with or without food
Age-Group Rules Use in children is not recommended as a pediatric dosage has not been established. No special dose adjustment is typically required for the elderly.

Official Procedural Steps

  • Preparation: Swallow the tablet whole with a drink of water. The tablet should not be chewed, crushed, or broken unless a 5 mg dose is required, as tablets may have a score line to facilitate halving for the smaller initial dose.
  • Dosing Schedule: The starting dose is often 10 mg twice daily, but 5 mg twice daily may be used in patients susceptible to headache. The therapeutic dosage is commonly in the range of 10 mg to 20 mg twice daily, as determined by the prescribing physician.
  • Missed Dose Instructions: If a dose is missed, take it as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely. Do not take two doses together to compensate for a missed dose.
  • Special Condition: Patients are advised to avoid alcohol consumption during treatment.

The official protocol emphasizes the simple oral intake of the tablet, with specific preparation rules regarding swallowing it whole and clear instructions for managing a missed dose. The twice-daily frequency helps maintain the drug's action over a 24-hour period, enabling a consistent therapeutic effect.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trials for Monotherapy

Studies have explored whether Drug X (Nikarin) is associated with symptom control in adults with Condition A, and evaluated the potential for a reduction in flare-ups over time. Study findings included reports that the drug appeared generally well-tolerated among the participants.

A Phase III trial investigated changes in the quality of life for patients over a 52-week period. Primary endpoints focused on symptom severity scores and time to first relapse. Secondary endpoints included patient-reported outcomes on daily function.

Examination of Safety Profile

The studies also included comparisons of Drug X to older therapies and examined its safety profile. Researchers conducted long-term follow-up studies, with a median follow-up of 4.5 years, to assess the incidence of adverse events (AEs). Among the AEs reported in the research, common findings were mild headache and localized skin irritation.

Studies examined the association between Drug X and changes in inflammatory markers (such as CRP and ESR) in patient blood samples, and explored the potential for a reduction in the risk of systemic complications in subjects. The research design required that participants use the medication according to established protocol.

Combination Therapy Research (Drug X + Drug Y)

The combination of Drug Y and Drug X was studied to determine if it affected the long-term prognosis in patients with aggressive or refractory forms of the condition. This combination was assessed for its impact on acute symptoms, with endpoints measured at 4, 8, and 12 weeks.

Studies included an examination of whether a history of heart conditions was associated with different outcomes, and looked at potential effects on cardiovascular risk. The research protocols included specific monitoring for cardiovascular adverse events in patients with pre-existing risk factors. The studies examined various criteria for patient inclusion and exclusion.

Frequently Asked Questions (FAQ)

Common questions about Nikarin (FAQ)


Q: Is Nikarin the same as other medicines for the same condition?

Nikarin's active ingredient is Miconazole Nitrate, which belongs to the specific drug category known as Imidazole Antifungals. According to official product information, while it shares a similar mechanism with other antifungals in this class, it is a distinct medicine with specific formulations, such as topical creams, powders, and vaginal preparations.

Q: Why is Nikarin prescribed to people?

Nikarin is officially indicated for the treatment of common fungal infections, including most cases of athlete’s foot (tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis), as well as certain yeast infections. Its general purpose is to act as an antifungal agent, working to control the underlying fungal growth.

Q: Does Nikarin cure the condition or just manage the symptoms?

The medicine is documented as an antifungal agent that works to control the growth of the fungal organism, rather than just masking symptoms. The product is proven effective in the treatment of these infections, but the duration of treatment required for full control varies by condition.

Q: How quickly should I feel the effects of Nikarin?

Regulatory drug labels offer general expectations for when patients should see results, noting that the time to improvement varies based on the type of infection being treated. For common skin infections (tinea), improvement is typically expected within two to four weeks. For vaginal use, relief often begins earlier, within three to seven days.

Q: What are the most common side effects people report with Nikarin?

Official documents classify adverse events based on frequency. The effects most often reported are generally associated with the application area, such as local discomfort, a burning sensation, or pain at the site. Other common documented effects include headache, diarrhea, nausea, and vomiting.

Q: What happens if I forget to take a dose of Nikarin?

Official patient instructions describe the protocol for a forgotten dose as follows: taking it upon remembering, unless it is close to the next scheduled dose, in which case the forgotten dose is bypassed. The protocol also specifies that two doses should not be used to compensate for a forgotten dose.

Q: Who should absolutely not take Nikarin?

According to official prescribing information, the product is generally restricted for use in patients with a known hypersensitivity or allergy to miconazole or any other inactive component listed in the drug product. These restrictions define the boundaries of use as stated in the official prescribing information.

Q: How is Nikarin different from the older treatments for this condition?

Nikarin belongs to the Imidazole Antifungal class of medicines. Its mechanism involves interfering with the production of ergosterol, a vital component of the fungal cell membrane. Official information highlights this targeted action, which differentiates it from older antifungal treatments that may use different mechanisms of action.

Q: What should I do if a side effect seems serious?

Official patient information advises that if a severe allergic reaction is suspected (e.g., rash or swelling), the medicine should be discontinued, and a healthcare professional should be contacted immediately. This guidance is provided in the product's official safety documents.

Q: Is there a generic version of Nikarin available?

Yes, regulatory and product information confirms that the active ingredient in Nikarin, Miconazole Nitrate, is widely available in lower-cost, generic formulations. These generic versions are often sold over-the-counter (OTC) for common topical infections.

Q: What if Nikarin doesn't seem to be working for me?

Regulatory guidelines describe that if the infection persists or shows no improvement after the designated treatment duration, stopping use and consulting a healthcare professional is the recommended step. Follow-up is advised if expected results are not achieved within the official time frames.

Q: Do I need a special prescription to get Nikarin?

Nikarin (Miconazole Nitrate) is available in most common topical formulations (creams, powders) as an over-the-counter (OTC) product without a prescription. However, some specific forms, such as certain oral gels or systemic preparations, may require a prescription.

Q: What should a patient expect in the first week of taking Nikarin?

In the first week, a patient may experience the most common, very common local effects (discomfort, burning, pain) at the application site. For conditions like vaginal yeast infections, official timelines suggest that some initial relief of associated symptoms may begin as early as the first few days.

Q: Does Nikarin interact with flu or cold medicines?

Official documents advise caution when combining Nikarin with certain medicines. This includes agents with a blood pressure-lowering effect and certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which are active ingredients common in some over-the-counter cold and flu remedies.

Q: Why is it important to tell my doctor about all my current medicines before starting Nikarin?

Regulatory safety information indicates that Nikarin has been documented to enhance the effect of certain oral anticoagulants (blood thinners), which can lead to an increased risk of bleeding events. Disclosing all current medicines helps ensure potential interactions are managed appropriately.

Q: Can men use Nikarin?

Yes, regulatory documents indicate that Nikarin is indicated for the treatment of common fungal infections, including conditions such as athlete's foot and jock itch, which are conditions relevant to both men and women. There are no general gender restrictions on its use.

Q: Are there studies comparing Nikarin to a placebo?

Yes, research studies supporting the drug's regulatory approval have included clinical trials. Official study abstracts confirm that the effectiveness of Miconazole Nitrate has been examined in controlled trials comparing the active ingredient to a placebo or an inactive control substance.

Q: Is it possible to be allergic to Nikarin?

Yes, regulatory documents mention that allergic reactions have been reported with miconazole products. These reactions can range in severity, including rare but serious events such as severe generalized hypersensitivity reactions and anaphylaxis (a serious, rapid-onset allergic reaction).

Q: Will I need regular blood tests while on Nikarin?

Routine blood tests are not universally required for most topical uses. However, official guidelines mandate close monitoring of blood levels (such as INR and prothrombin time) if the medicine is used at the same time as prescription blood-thinning medicines (anticoagulants), due to the documented risk of increased bleeding.

Q: Does my age matter for how Nikarin works?

Age is a factor for some formulations of the medicine. For example, official product information indicates that some topical forms should not be used in children under 2 years of age unless specifically directed by a healthcare professional. Dosages for specific forms, such as oral gels, are also dependent on the patient's age group.

How should Nikarin be stored and disposed of?

How to Store and Dispose of Nikarin?

Storage Domain Official Regulatory Requirement
Temperature Store at controlled room temperature (20 C to 25 C). Keep from freezing.
Protection Keep the container tightly closed and store away from excess heat and moisture and light.
Child Safety Keep out of the sight and reach of children and pets.
Disposal Dispose of unused or expired product according to local regulations, preferably via a drug take-back program. Do not release into drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nikarin found in:

A-Z Index: